📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Expérience confirmée
26 ans d'exercice en rhumatologie — recul clinique solide
26ans d'exercice (thèse 2000)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Direction : Abdellatif Tazi
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Efficacy and safety of DANAZOL for pulmonary fibrosis or bone-marrow failure associated with telomere-related gene mutation
2025ArticleERJ Open Research
Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease
2021ArticleJournal of Investigative Dermatology
Slowly or Nonresolving Legionnaires’ Disease: Case Series and Literature Review
2020ArticleClinical Infectious Diseases
COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD
2018ArticleEuropean Respiratory Journal
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis
2016ArticleEuropean Respiratory Journal
DC-SIGN induction in alveolar macrophages defines privileged target host cells for mycobacteria in patients with tuberculosis.
2005ArticlePLoS Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Medscape · 29/01/2020
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5TVkt1SmJ6U1BWTlM0SDRXZktaSkljOC11TjdoR0F1ZVFmaVF3d3M3a2ExM1VWb2o1VVBYeklhRTkyRWg5VGJFNWNKeGlOYm9VM3Y5dGMtN05ma1dVamc?oc=5" target="_blank">L’azithromycine en pneumologie, un médicament pas si anodin</a> <font color="#6f6f6f">Medscape</font
The European respiratory journal · 2016
Telomerase reverse transcriptase ( TERT ) or telomerase RNA ( TERC ) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing of TERT / TERC genes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis. We retrospectively analysed all the genetic diagnoses made between 2007–2014 in patients with pulmonary fibrosis. We evaluated the prevalence of TERT / TERC disease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival. 237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested for TERT / TERC DAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence of TERT / TERC DAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2% versus 16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40–60 years. Transplant-free survival was lower with than without TERT / TERC DAV (4.2 versus 7.2 years; p=0.046). TERT / TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival.
The European respiratory journal · 2018
The COPD Patient Management European Trial (COMET) investigated the efficacy and safety of a home-based COPD disease management intervention for severe COPD patients.The study was an international open-design clinical trial in COPD patients (forced expiratory volume in 1 s <50% of predicted value) randomised 1:1 to the disease management intervention or to the usual management practices at the study centre. The disease management intervention included a self-management programme, home telemonitoring, care coordination and medical management. The primary end-point was the number of unplanned all-cause hospitalisation days in the intention-to-treat (ITT) population. Secondary end-points included acute care hospitalisation days, BODE (body mass index, airflow obstruction, dyspnoea and exercise) index and exacerbations. Safety end-points included adverse events and deaths.For the 157 (disease management) and 162 (usual management) patients eligible for ITT analyses, all-cause hospitalisation days per year (mean±sd) were 17.4±35.4 and 22.6±41.8, respectively (mean difference −5.3, 95% CI −13.7 to −3.1; p=0.16). The disease management group had fewer per-protocol acute care hospitalisation days per year (p=0.047), a lower BODE index (p=0.01) and a lower mortality rate (1.9%versus14.2%; p<0.001), with no difference in exacerbation frequency. Patient profiles and hospitalisation practices varied substantially across countries.The COMET disease management intervention did not significantly reduce unplanned all-cause hospitalisation days, but reduced acute care hospitalisation days and mortality in severe COPD patients.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of investigative dermatology · 2021 · Journal Article
Talvard-Balland N, Sutra Del Galy A, Michonneau D, Le Buanec H, et al.
The European respiratory journal · 2018 · Journal Article
Kessler R, Casan-Clara P, Koehler D, Tognella S, et al.
PLoS medicine · 2005 · Journal Article
Tailleux L, Pham-Thi N, Bergeron-Lafaurie A, Herrmann JL, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020 · Case Reports
Pouderoux C, Ginevra C, Descours G, Ranc AG, et al.
The European respiratory journal · 2016 · Journal Article
Borie R, Tabèze L, Thabut G, Nunes H, et al.
The European respiratory journal · 2016 · Journal Article
Borie R, Tabèze L, Thabut G, Nunes H, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020 · Case Reports
Pouderoux C, Ginevra C, Descours G, Ranc AG, et al.